Roivant Sciences Ltd. Common Shares vs Vanguard Total International Stock Index Fund ETF — how do they compare? Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B), while Vanguard Total International Stock Index Fund ETF trades at $84.51 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 26.5× Roivant Sciences Ltd. Common Shares's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (5,738,571 versus 4,890,695). Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 0 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| ROIV | VXUS | |
|---|---|---|
Market Cap | $25.09B | $665.70B |
Volume | 5,738,571 | 4,890,695 |
Sector | Health | Sector/Thematic |
52-Week High | $41.81 | $88.41 |
52-Week Low | $16.04 | $72.17 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $21.36B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VXUS, the Vanguard Total International Stock ETF, is trading at $84.78, down 1.19% on the day, with a bearish technical signal driven by moving averages. The ETF provides diversified exposure to international developed and emerging markets outside the U.S. Recent news highlights its role in portfolio diversification and long-term growth potential, with several financial firms increasing their positions in Q2 2026.
The outlook for VXUS hinges on international market performance relative to the U.S., offering a hedge against domestic downturns. Key risks include currency fluctuations, geopolitical tensions, and the ETF's inability to reclaim foreign tax credits in IRAs. Its low-cost, broad diversification presents a strategic opportunity for long-term investors seeking global equity exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →